Ninlaro (ixazomib)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- ixazomib
- Company
- Takeda Pharma A/S
- Status
- Authorised
- Therapeutic area
- Multiple Myeloma
- CHMP opinion
- Thu 15 Sep 2016
- EU approval
- Mon 21 Nov 2016
- Designations
- Orphan
- Application
- EMEA/H/C/003844
- ATC
- L01XG03
- Official record
- www.ema.europa.eu
Indication
Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Ninlaro
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.